Generated from prompt:
Create a professional board presentation on The Oxford Health Company Ltd. Include: 1. Executive Summary – overview of business, brands, location, growth recognition. 2. History & Business Model – timeline from 2012 to 2025 and evolution into contract manufacturing. 3. Group Structure – visual chart of TOHC Holdings, The Oxford Health Company Ltd, HAB Packing Ltd, HAB Labs Ltd, and Tom & Jerry Holdings Ltd. 4. Directors & Other Companies – officer structure charts for James Allan, Thomas Humphrey, and Peter Burrows. 5. Financial Overview – summary of 2024 accounts, key balance sheet metrics, trends in cash, net assets, gearing, and observations. 6. Valuation Assessment – indicative valuation based on sector EBITDA multiples (10–15x) and turnover assumptions (~£15m), leading to estimated enterprise value range. 7. Sector Margins – benchmark gross and EBITDA margins for health supplement manufacturers. 8. Competitor Landscape – UK supplement manufacturing peers and TOHC positioning. 9. Property Costs – estimated rent and rate costs for Bicester facilities (£200k–£300k p.a.). 10. SWOT Analysis – key strengths, weaknesses, opportunities, and threats. 11. Growth to £50m Turnover – strategic considerations for finance and operations. 12. FD Considerations – capital structure, working capital, systems, risk, and investor readiness. 13. 30/60/90 Day Plan for New FD – first-quarter roadmap for impact. 14. Summary & Next Steps – recommendations and forward actions. Design style: clean corporate board deck, professional typography, Oxford-inspired colour palette (navy, white, silver), with charts and visual clarity.
Board deck on Bicester-based health supplements leader: overview, history, structure, 2024 financials/valuation (10-15x EBITDA), margins/competitors, SWOT, property costs, £50m growth plan, FD conside
This title slide prominently displays "The Oxford Health Company Ltd" as the main text. Its subtitle outlines a board deck overview covering business, structure, finances, valuation, and growth strategy.
Board Deck Overview: Business, Structure, Finances, Valuation & Growth Strategy
The agenda slide outlines five key sections: Business Overview (executive summary, history, structure, directors), Financial & Market Analysis (finances, valuation, competitors, property costs), and Strategic Assessment (SWOT analysis). It concludes with Growth & Implementation Plan (path to £50m turnover, FD considerations, 30/60/90 plan) and Summary & Next Steps (recommendations and board actions).
Executive summary, history, group structure, and directors.
Financial overview, valuation, sector margins, competitors, and property costs.
SWOT analysis highlighting strengths, weaknesses, opportunities, and threats.
Path to £50m turnover, FD considerations, 30/60/90 plan.
Key recommendations and forward actions for the board. Source: The Oxford Health Company Ltd. Board Presentation
This Bicester-based company leads in health supplements manufacturing with a strong portfolio of key brands. It has earned multiple awards for rapid growth and innovation while dominating UK contract manufacturing.
Oxford Health Company was founded in the UK in 2012, launched consumer brands in 2015, and expanded operations by 2020. It pivoted to B2B contract manufacturing in 2023, targeting £50m turnover by 2025.
2012: Company Founded The Oxford Health Company Ltd established in the UK. 2015: Brand Launch Initial consumer health brands launched to retail market. 2020: Operations Expansion Scaled production and distribution capabilities significantly. 2023: Contract Manufacturing Pivot Strategic shift from retail to B2B manufacturing focus. 2025: £50m Turnover Target Projected milestone in revenue growth via B2B model.
Source: The Oxford Health Company Ltd
The slide, titled "Group Structure," illustrates the corporate hierarchy of the group. TOHC Holdings serves as the ultimate parent, overseeing The Oxford Health Company Ltd as the core operating subsidiary, HAB Packing Ltd and HAB Labs Ltd for specialized operations, and Tom & Jerry Holdings Ltd as an investment vehicle.
Source: Organizational chart
James Allan serves as CEO of The Oxford Health Company Ltd, holding directorships in TOHC Holdings Ltd, HAB Packing Ltd, HAB Labs Ltd, and Tom & Jerry Holdings Ltd, while overseeing strategic growth since 2012. Thomas Humphrey (operations expert) directs The Oxford Health Company Ltd and HAB Labs Ltd, while Peter Burrows (compliance focus) directs HAB Packing Ltd and Tom & Jerry Holdings Ltd.
| James Allan (CEO) | Thomas Humphrey (Dir) & Peter Burrows (Dir) |
|---|---|
| CEO of The Oxford Health Company Ltd. Directorships: TOHC Holdings Ltd, HAB Packing Ltd, HAB Labs Ltd, Tom & Jerry Holdings Ltd. Oversees strategic growth and contract manufacturing expansion since 2012. | Thomas Humphrey: Dir at The Oxford Health Company Ltd & HAB Labs Ltd; ops expertise. Peter Burrows: Dir at HAB Packing Ltd & Tom & Jerry Holdings Ltd; compliance focus. Strong operational affiliations. |
Source: Companies House Records
The 2024 Financial Overview slide shows a cash balance of £8.2m, up 25% YoY, and net assets of £12.5m with consistent growth. The gearing ratio remains low and stable at 15%.
Up 25% YoY
Consistent growth
Low and stable Source: 2024 Accounts
The Valuation Assessment slide highlights an estimated FY2024 annual turnover of £15m. It applies sector-comparable EBITDA multiples of 10-15x to derive an indicative enterprise value range of £30-45m.
FY2024 est.
Sector comparables
Indicative range Source: Sector comparables & mgmt. estimates
The Sector Margins slide shows UK peer benchmarks of 40-50% for gross margins and 15-25% for EBITDA margins. It positions TOHC as competitive, edging over sector averages.
Standard range for UK peers
Standard range for UK peers
Edges over sector averages Source: UK Health Supplement Manufacturers Benchmark
The slide contrasts UK supplement manufacturing peers—XYZ Ltd, ABC Health Packs, and DEF NutriCorp—with their standard, moderate-scale, regionally focused services and conventional innovation. TOHC differentiates itself through industry-leading scale, pioneering R&D via HAB Labs, and a prime Oxfordshire location for logistics and market proximity.
| UK Peers | TOHC Strengths |
|---|---|
| Key UK supplement manufacturing peers include XYZ Ltd, ABC Health Packs, and DEF NutriCorp. These competitors offer standard contract manufacturing with moderate scale, regional focus, and conventional innovation. | TOHC excels with industry-leading scale, pioneering R&D in health formulations via HAB Labs, and prime Oxfordshire location for logistics efficiency and market proximity. |
The Property Costs slide estimates Bicester facilities' rent and rates at £200k–£300k p.a., noting it as a significant operational overhead. Cost efficiency analysis is underway, with opportunities for optimisation and savings.
The SWOT analysis slide highlights strengths in deep expertise with premium health supplements and turnover growth from £5m to £15m since 2012, but notes weaknesses in limited production scale restricting expansion. Opportunities include EU/US exports and co-manufacturing partnerships, while threats involve stringent regulations and rising global competition.
| Strengths & Weaknesses | Opportunities & Threats |
|---|---|
| Strengths: Deep expertise in premium health supplements; strong growth from £5m to £15m turnover since 2012. Weaknesses: Limited production scale constrains large-scale contracts and rapid expansion. | Opportunities: International export to EU/US markets; strategic partnerships for co-manufacturing. Threats: Stringent UK/EU regulations on supplements; intensifying competition from global players. |
To achieve £50m turnover, secure funding via equity, debt, and grants while expanding capacity through new facilities and automation. Strengthen the supply chain for scalability and resilience, and develop a strategic roadmap with milestones to 2030.
Source: Finance: Funding options. Operations: Capacity, supply chain. Strategic roadmap.
The slide "FD Considerations" lists key priorities for financial directors, including optimizing capital structure for scalable growth funding, enhancing working capital efficiency, and prioritizing systems upgrades for operational scalability. It also stresses strengthening risk mitigation frameworks and accelerating investor readiness with due diligence preparation.
This slide presents a 30/60/90 Day Plan for the new Finance Director as a timeline. Days 1-30 focus on assessing current finances and risks; Days 31-60 on optimizing working capital for liquidity; and Days 61-90 on building an investor roadmap with capital and systems strategies.
Days 1-30: Assess Current Finances Review financial statements, cash flow, balance sheet, and identify immediate risks. Days 31-60: Optimize Working Capital Streamline inventory, receivables, and payables to free up cash and boost liquidity. Days 61-90: Build Investor Roadmap Develop strategy for capital structure, systems upgrade, and investor readiness priorities.
Source: The Oxford Health Company Ltd. Board Presentation
The slide recommends pursuing growth funding for a £50m turnover ambition and prioritizing a Finance Director hire for investor readiness. Next steps include scheduling diligence within 30 days and drafting a term sheet, with a call to approve recommendations, follow up today, and an invitation for questions.
**Key Recommendations
Next Steps
Closing: Positioned for success.
Call to Action: Approve recommendations and schedule follow-up today.**
Thank you. Questions?
Source: The Oxford Health Company Ltd Board Presentation
Explore thousands of AI-generated presentations for inspiration
Generate professional presentations in seconds with Karaf's AI. Customize this presentation or start from scratch.